EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study

Hui Liu, Hui Xu, Peiru Chi, Zinan Feng, Xiaojun Xu, Danian Nie, Xudong Li, Xinquan Liang, Zhiping Fan, Na Xu, Fen Huang, Ren Lin und 8 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27516 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Hui Liu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Protein Kinase Inhibitors. Die Arbeit nennt 6 Literaturangaben. Gefördert von: Clinical Research Program of Nanfang Hospital, Southern Medical University, National Key Research and Development Program of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapse is the major cause of treatment failure in Philadelphia chromosome‐positive (Ph + ) acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (allo‐HSCT). This study aimed to evaluate the effect of a prophylactic tyrosine kinase inhibitor (TKI) strategy on relapse in this population. Patients were assigned to prophylactic or control groups based on measurable residual disease (MRD) pre‐transplantation. The primary endpoint was the cumulative incidence of relapse. A total of 110 patients with Ph + ALL undergoing allo‐HSCT were enrolled in this prospective study. Thirty‐eight patients with positive MRD pre‐transplantation were included in the prophylactic group, and 72 with negative MRD pre‐transplantation were included in the control group. The 4‐year cumulative incidence of relapse was 25.3% (95% CI: 12.1%–41.0%) and 20.3% (11.6%–30.7%; HR = 1.272, 95% CI: 0.551–2.940, p = .549), and non‐relapse mortality was 10.5% (3.3%–22.7%) and 9.7% (4.2%–17.9%; HR = 1.094, 95% CI: 0.320–3.738, p = .928) in the prophylactic and control groups. The 4‐year overall survival was 71.8% (53.2%–84.1%) and 84.1% (72.9%–90.9%; HR = 1.746, 95% CI: 0.741–4.112, p = .196), and leukemia‐free survival was 64.1% (45.8%–77.7%) and 70.0% (57.6%–79.4%; HR = 1.212, 95% CI: 0.607–2.421, p = .585) in the prophylactic and control groups. Our results suggest that prophylactic TKI post‐HSCT in patients with positive MRD pre‐transplantation can produce outcomes comparable to negative MRD pre‐transplantation without TKI post‐HSCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein Kinase InhibitorsHumansMaleFemaleAdultProspective StudiesMiddle AgedAdolescentYoung AdultTransplantation, HomologousPhiladelphia ChromosomeRecurrenceAllograftsTyrosine Kinase Inhibitors

Substanzen

Protein Kinase InhibitorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Department of Hematology, Clinical Medical Research Center of Hematology Diseases of Guangdong Province, Guangzhou, China.
  • Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
  • Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Hematology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Hematology, First People's Hospital of Chenzhou, Chenzhou, China.

ORCID-Profile: Hua Jin, Hongsheng Zhou, Qifa Liu, Li Xuan

Förderung

  • Clinical Research Program of Nanfang Hospital, Southern Medical University
  • National Key Research and Development Program of China
  • Natural Science Foundation of Guangdong Province
  • National Natural Science Foundation of China

Zitieren

APA

Liu, H., Xu, H., Chi, P., Feng, Z., Xu, X., Nie, D., Li, X., Liang, X., Fan, Z., Xu, N., Huang, F., Lin, R., Wang, Z., Jin, H., Zhou, H., Guo, X., Lin, D., Sun, J., Liu, Q., & Xuan, L. (2025). A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study. American Journal of Hematology. https://doi.org/10.1002/ajh.27516

Vancouver

Liu H, Xu H, Chi P, Feng Z, Xu X, Nie D, et al. A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study. American Journal of Hematology. 2025. doi:10.1002/ajh.27516

BibTeX
@article{Liu2025,
  author = {Liu, Hui and Xu, Hui and Chi, Peiru and Feng, Zinan and Xu, Xiaojun and Nie, Danian and Li, Xudong and Liang, Xinquan and Fan, Zhiping and Xu, Na and Huang, Fen and Lin, Ren and Wang, Zhixiang and Jin, Hua and Zhou, Hongsheng and Guo, Xutao and Lin, Dongjun and Sun, Jing and Liu, Qifa and Xuan, Li},
  title = {A prophylactic tyrosine kinase inhibitor strategy based on measurable residual disease pre‐transplantation for Ph + acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A prospective multicenter cohort study},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27516}
}
Kostenlos starten →